Esperion Therapeutics, Inc. (ESPR) P/E Ratio History
Insufficient DataValuation data unavailable. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ESPR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ESPR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ESPR P/E vs Peers
Cardiovascular & Renal Drugs peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $5B | 5.5Lowest | - | -12% | |
| $3B | 8.8 | - | +68% | |
| $7B | 25.7 | - | -22% | |
| $12B | 25.4 | 1.11Best | -25% | |
| $1.3T | 46.2 | 1.60 | +96%Best | |
| $164B | 41.1 | - | -4% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ESPR Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ESPR — Frequently Asked Questions
Quick answers to the most common questions about buying ESPR stock.
What is ESPR's P/E ratio?
Esperion Therapeutics, Inc. (ESPR) trailing twelve-month P/E ratio is N/A, based on TTM diluted EPS of N/A. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is ESPR stock overvalued or undervalued?
ESPR current P/E: N/A. 5-year average P/E: N/A. Percentile: N/A.
Is ESPR stock expensive?
ESPR is fairly valued relative to its own history. The current P/E of N/A is near the 5-year average of N/A (N/A percentile of historical range).
What is ESPR's historical P/E range?
Over the past 5 years, ESPR's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of N/A places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does ESPR's P/E compare to the S&P 500?
ESPR current P/E: N/A. S&P 500 median P/E: 21.9x.
How does ESPR's valuation compare to Healthcare peers?
Esperion Therapeutics, Inc. P/E of N/A can be benchmarked against Healthcare peers in the comparison table on this page.
What is ESPR's PEG ratio?
ESPR PEG ratio is N/A. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ESPR's earnings yield?
ESPR earnings yield is N/A, the inverse of its N/A P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.